Abstract. We propose in this article to compare the eciency of two chemotherapeutic schedules: the traditional and the metronomic. For this, we develop a new mathematical model describing the growth dynamics of tumor and endothelial cells as well as the impact of molecules as oxygen or vascular endothelial growth factor on this dynamics. The model construction: biological assumptions, description of the equations and their discretization, constitutes the core of the article. Numerical experiments illustrate the expected behavior of the disease under the two chemotherapeutic schedules.
Introduction
Metronomic chemotherapy.
Cancer is a major cause of death worldwide and tends to become the rst cause of death in the industrialized countries. Many studies were and are still designed to improve the ecacy of existing anti-cancer treatment by optimizing the administration schedule. Based on the concept that the more anti-cancer drug are administered to the patient, the more tumor cells may die, the chemotherapeutic schedule traditionally used in clinical practice consists in the administration of the maximal dose of anti-cancer drugs that can be tolerated by the patient, also called the maximal tolerated dose (MTD). As chemotherapy kills not only cancer cells but any cell in state of rapid proliferation, MTD induces serious toxicities, depending on the type of anti-cancer agent used, and thus requires prolonged breaks (generally of 2-3 weeks in duration) between successive cycles to allow recovery from the harmful side eects but also time for cancer tissue to eventually resume growth. Moreover, in the long term, MTD ecacy can be hampered by the propensity of cancer cells to develop resistance to the drug. Hence, toxicity as well as the possible emergence of resistance are main disappointing issues with such chemotherapeutic schedule. In a search for new targets as well as new strategies to ght cancer, Judah Folkman's works on tumor angiogenesis at the beginning of the 70's brought outstanding biological knowledge about tumor biology and initiated a pioneer switch in treatment thinking. Indeed, these works showed that angiogenesis, the process of new blood vessel formation, plays a central role in both local tumor growth and distant metastasis [22, 23] .
Therefore, it has become increasingly evident that agents which interfere with blood vessel formation also block tumor progression. Although promising results were initially obtained with such anti-angiogenic treatments, clinical data suggest resistance to these drugs is a very real problem. A new alternative arose in 1991 when R.
Kerbel suggested that anti-cancer agents may be able to target tumor vasculature [34] . Then, Klement et al. [36] and mainly Browder et al. [11] showed that a more frequent, regular and lower-dose therapy, administered at one-third of the MTD, had highly anti-angiogenic and anti-tumor eects on several mouse tumor cell lines. This kind of approach was then termed metronomic by Hanahan et al. [28] . Such a protocol, that consists in the frequent, even daily, administration of chemotherapeutics at doses signicantly below the MTD, with no prolonged drug-free breaks, seems to inhibit tumor growth primarily through anti-angiogenic mechanisms while signicantly reducing undesirable toxic side eects. Both, resistant or not, tumors cells eventually get killed [1, 48] . Recent ndings suggest that metronomic chemotherapy might also restore anti-cancer immune response and induce tumor dormancy [48] . Nowadays, there is real clinical needs for dening the best schedule of drug administration and related parameters (doses of agent, choice in combination, treatment duration...).
Resorting to mathematical modeling appears as a good way to help clinicians to design optimal administration schedules, for instance by generating hypotheses to explain the eect of metronomic chemotherapies on the vascular network and by performing optimization numerical simulations.
Mathematical models.
Ecient cancer therapy requires a throughout and upgraded understanding of cancer biochemistry, pharmacology, kinetics and clinics. By using mathematical models, numerous authors have attempted for several years to manage all the available information in order to optimize cancer therapy ( [25] ). To optimize drug ecacy, both drug amounts (intensication) and administration schedule (densication) should be determined to ensure a desired rate of tumor cell kill with acceptable toxicity. Twenty years ago, the group of D. Barbolosi and A. Illiadis developed a mathematical model able to calculate densied administration protocols [3, 31] .
Their approach has been validated through two pioneer works; in [41] they illustrate how such approach may assist to design a phase I trial in oncology, in [53] they report a phase I clinical trial including twenty patients with metastatic breast cancer whose treatment were driven/optimized by a mathematical model. The model consists in a Gompertz model with a death term that represented the cytotoxic action of the chemotherapeutic agent. Pharmacokinetic (PK) and pharmacodynamic (PD) models are used for the cytotoxic action of the chemotherapeutic agents on the cancer cells and for the hematological toxicities. We also can mention few optimization problems analyzed to determine optimal drug infusion schedules taking into account drug toxicity [6, 7, 19, 37, 4446, 51] . Note that these articles studied the optimization of one anti-cancer therapy (chemotherapy, anti-angiogenic therapy, ...) or of combination of several ones. In order to be more realistic such optimization problems can not rely on simple Gompertz law for tumor growth and require more sophisticated model taking into account angiogenic process. Among the models of angiogenesis, let us mention the pioneer works made by the group of J. Folkman [22, 23, 26, 27] since the beginning of the seventies. Several complex models of angiogenesis were then developed, for instance in [2, 1217, 35, 47, 49] . Such angiogenesis models were also coupled to tumor growth models in order to study the tumor vascular growth stage, for instance in [8, 10, 12, 18, 30, 47, 50, 55] . In [8] , to study the eects of an anti-angiogenic therapy on tumor growth, the authors coupled, via the concentration of oxygen, the avascular tumor growth model developed by Bresch et al. in [9] with a new multiscale PDE model of angiogenesis. This angiogenesis model accounts for endothelial cell (cells that constitute blood vessel inner wall) density and for pro-and anti-angiogenic agent concentrations.
Endothelial cells were assumed to be in two dierent states, that can be named active and non active, according hal-00751645, version 1 -13 Nov 2012 to their ability to respond to pro-angiogenic signals emitted by quiescent tumor cells. Thus active endothelial cells were assumed to proliferate and migrate in the direction of the gradient of pro-angiogenic concentration, i.e. towards the tumor mass, whereas active endothelial cells were supposed not to proliferate nor migrate but to constitute the wall of ecient blood vessels, source of oxygen. Non active endothelial cells were assumed to be able to be active whereas the inverse was assumed to be impossible, i.e. active endothelial cells could not become non active. By means of this model, Billy et al. analyzed the eects on the vascular network, and so on tumor growth, of several treatment schedules of an anti-angiogenic therapy consisting in promoting the secretion of an anti-angiogenic agent by tumor cells.
Few works exist on the metronomic schedules modeling. Hahnfeldt et al. [26] Majumder and co-workers [39, 40, 42] compared the eects of metronomic chemotherapy to conventional chemotherapy infusion schedules by means of discrete models. For instance, in [39] the authors developed a discrete model (dened on a point grid) that includes the tumor system, the microvasculature system, and the nearby blood vasculature system. This model also takes into account a tumor angiogenic factor and bronectin that are known to guide the endothelial cell motion. At each point of the grid and for each time step, the microvascular cell diameter is given by a discrete equation that depends on the probabilities of an individual endothelial cell to move on the nearby points of the grid. The time evolution of the tumor mass was supposed to depend on the microvascular cell diameter at the tumor site. This model enabled to compare the conventional maximum tolerable dose (MTD) strategy with the metronomic one. The authors concluded that metronomic chemotherapy was more ecient to control tumor growth than the maximum tolerable dose chemotherapeutic strategy. In [42] , the authors considered two types of tumor cells, i.e. resistant and sensitive to the drug, and the clearance rate of the excretory system that is known to inuence the drug concentration and so to inuence its toxicity.
The impact of metronomic chemotherapy and conventional chemotherapy on both metastatic and primary tumors, is investigated in [5] by means of a structured transport equation endowed with non local boundary condition. The tumor growth speed, they used was inspired by [27] .
For an unresectable glioblastoma, a phenomelogical mathematical model is proposed in [21] able to take into account a classical MTD (Maximum Tolerated Dose) chemotherapy regimen (whose primary targets are the tumor cells) as well as a metronomic chemotherapy regimen (whose primary targets are the tumor endothelial cells) for the administration of Temozolomide (Temodal) in order to compare the eectiveness of these two types of protocols. The model is built from 5 natural hypotheses: without treatment the tumor growth follows a Gompertz model, endothelial cells are more sensitive to temozolomide than cancer cells, the anti-angiogenic eect blocks tumor growth, endothelial cells are genetically stable and thus don't develop resistance to temozolomide, the main chemotherapeutic is due to drug resistance; thus in particular this model of tumor growth take into account this resistance.
As far as the resistance problem is concerned, let us mention the works of [24, 32, 33, 52] . For instance, Jackson et al. [33] The chemotherapy is a cytotoxic agent supposed to kill all proliferating cells (tumor cells and endothelial cells). In contrast to ECs, tumor cells can develop resistance to chemotherapy, depending on the amount of drug already administered (cumulative drug dose).
Equations
All the variables of the model depend on time t and space x ∈ R d with d = 2 or d = 3.
The variables appearing in the model are directly linked to the biological entities we considered, i.e. Oxygen. Oxygen is supposed to diuse in the surrounding tissue from the functional blood vessels represented by active ECs. It is also assumed to disappear because of natural degradation. The cell consumption is neglected and the concentration is maintained at a maximal xed value o max 2 in the active blood vessel. We assume that the time scale associated to oxygen diusion is very small compared to the one of cell division, so that the oxygen dynamics is governed by a quasi-static equation: Angiogenic balance. The angiogenic balance resumes the eects of pro-and anti-angiogenic factors. We supposed that they diuse in the tissue. They are produced by quiescent tumor cells at a constant rate, and are naturally eliminated. As we did with oxygen, we assumed that the dynamics of angiogenic factors is also governed by a quasi-static equation: active as soon as the total ECs density was higher than a given threshold ec min . These cells are also supposed to disappear due to necrotic and tumor cells local dominance. Active ECs are to recolonize slowly the space in case of low ECs density. Thus, the evolution of the active EC density is given by:
where D ec represents the diusion coecient, µ stab the constant transition rate from non active to active ECs, β p,eca , β q,eca , β d,eca the elimination rates due to necrotic and tumor cell local dominance, α recol the proliferation rate, µ inst Sig(a ng , r ang,ec , s ang,ec ) the transition rate from non active to active ECs where µ inst is assumed to be constant, and where the function Sig is dened by: Sig(w, y, z) = w 1 + e −y(w−z)
Non active ECs. As said before, we assume that non active ECs derived from active ECs as soon as angiogenic factors reach a threshold s ang,ec . They begin to proliferate until the total EC density reach a maximal value ec max = 1. Non active EC loss is supposed to be induced by stabilization into active ECs, by elimination due to necrotic and tumor cell local presence and by the cytotoxic eect of the chemotherapy. Thus non active EC density follows the equation:
where α ec represents the proliferation rate, µ inst the destabilization rate, µ stab the stabilization rate, β p,ecna , β q,ecna and β d,ecna the loss rates due to tumor cell presence, δ ec the natural decay rate and η ec the cytotoxic eect rate. The function Sig is previously dened.
Note that for both ECs, the migration under growing tumor pressure has been neglected.
Tumor cells. We distinguish among the tumor cells, the proliferant and the quiescent cells. Proliferant cells divide with a constant rate α p and are supposed to become quiescent if the oxygen level falls below a given threshold h pq . Quiescent tumor cells are supposed to become proliferant if the oxygen level exceeds a given threshold h qp or to die of the oxygen level falls below a given threshold h qd . Tumor cell proliferation and death induce a passive transport movement whose velocity is denoted by v (cf. below for more details about v). Proliferant tumor cells, as well as all proliferant cells, are also supposed to be killed by the cytotoxic eect of the chemotherapy. So the evolution of the proliferant and quiescent tumor cell densities is given by:
where 
where f − is dened above and h md stands for the oxygen threshold, γ md is a degradation rate.
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Necrotic / apoptotic tumor and healthy cells.
Necrotic cells are supposed to result from quiescent cells and healthy cells if the oxygen level falls below some threshold h qd and h md . They are gradually eliminated by macrophages due to inammatory processes: we assume that these macrophages diused from the surrounded functional blood vessels so we suppose that their concentration was proportional to the oxygen concentration. Necrotic cells are also supposed to be transported with velocity v by the growing tumor mass. So the evolution of the density of necrotic cells is given by:
where f − is dened above and where δ infl represented the degradation rate due to macrophages.
Velocity. We assume that the cell movement due to the growing tumor mass follows a Darcy's law:
where p is the pressure induced by the tumor growth. The velocity is supposed to be independant of the type of cells.
To prescribe an expression for the pressure p, we assumed that the total number of tumor, necrotic and healthy cells P + Q + D + M is constant (equal to 1) with respect to time when no chemotherapy is applied.
So by summing equations (5) to (8), and using Darcy's law, we get:
Chemotherapeutic agent. The chemotherapy acts on any proliferating cells, that is here on both proliferating tumor cells and non active ECs. We rst assume that the concentration of the drug has to reach a threshold c min,ct to be ecient on the proliferating tumor cells and a threshold c min,aa on endothelial cells. As tumor cells tend to develop drug resistance, we assumed that this drug response was exponentially decreasing according to the total drug exposure expo(t) = The model. The model equations are summarized below.
where Sig(w, y, z) = w 1 + e −y(w−z) Figure 2) . Initial conditions. We restrict in this paper to radially initial conditions (at time t = 0):
where tumor corresponds to the initial tumor location, i.e., a circle (in 2D) or a sphere (in 3D) centered on the space location (0, 0) (in 2D), (0, 0, 0) (in 3D), whose radius is equal to r tumor (see gure 3). 
, r i+ 
We use a semi-implicit Euler scheme for the time discretization. The terms treated implicitely are specied below:
, h md )m n Note that this discretization preserves the mass balance equation p + q + d + m = Cte, ie for all n,
The nite volume discretization in space (see [20] ) consists in multiplying all the equations by r d−1 , with d being the space dimension, and integrating the resulting equations over J i . The diusion terms
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are approximated by hr
is given by the boundary condition at r = R. Note that the velocity v is then naturally approximated at the vertices r i+ 1 2 of the segments J i by v i+
can be taken equal to zero without loss of generality since it is always multiplied by r 1 2 = 0. The transport terms are then approximated thanks to an upwind scheme
is given by the boundary condition at r = R.
Parametrization
Values of most of all parameters used in the model were not directly given in the literature. By cross-checking data available in the literature, we could solely deduce realistic values of the model parameters. Consequently, basing ourselves on biological observations, we dened a set of rules to prescribe the model dynamics. We determined parameter values by hand so that the simulation results satisfy all these rules.
The basis of rules is a set of biological facts that enabled to limit the range of the realistic values of the model parameters. If this method did not make it possible to determine single set of parameter values, it enabled us to dene sets of parameter values that led to realistic model dynamics. These biological rules are given below.
(1) A tumor can grow until a diameter of 2 or 3 mm without developing angiogenesis.
(2) In absence of new vascularization, the tumor stays dormant. tumor growth. Of course, a tumor able to produce angiogenic factors starts its growth without modifying the vascularization thus it starts with an avascular growth.
We recall that Figure 3 presents the initial tumor for all the following simulations. Particularly, we assume that the tumor has an initial diameter of 0.2 millimeter and is centered in the domain (so centered at r = 0). Figure 4 presents the time evolution of the tumor in an avascular setting (α V = 0) and in a vascular setting (α V > 0). Times are in weeks and distances in millimeters. We observe that in both cases, proliferant cells reproduce and make the tumor grows until the vascularization is not sucient to provide energy for every cell. Part of the proliferant tumor cells becomes quiescent (from t ≥ 4) and then die (from t ≥ 7). Then in the avascular case, the elimination of dead cells by the immune system compensates with the proliferation of proliferant cells and the tumor stops growing (from t ≥ 15) and the all system converges to a stationary state.
Meanwhile in the vascular case, once quiescent cells appeared, they produce angiogenic factors which triggers proliferation of endothelial cells. The endothelial cells thus settle at the periphery of the tumor, supplying oxygen to the tumor and allowing growth to pursue.
We observe that the tumor grows until it reaches a maximum diameter between 2 and 3 mm. The tumor does not shrink, it stays still waiting for better conditions for growing. This result is consistent with the biological literature [29, 38, 54] . The Maximal Tolerated Dose (MTD) protocol is the protocol described in [43] . The drug (Temozolomide) is administered with 5 intravenous injections of 200 mg/m 2 /day at the rst 5 days of a cycle. The cycle is assumed to last for 21 days. In the sequel, the standard patient is supposed to have a body area around 1.7m 2 . We simulate here the case where 12 cycles of chemotherapy are administered.
The metronomic protocol is taken from [4] . The drug (Temozolomide) is per os administered each day during 42 days at a dose of 65 mg/m 2 /day or 85mg/m 2 /day, followed by a pause of 7 days. The number of cycles of chemotherapy is not limited in that case. Figure 6 compares the evolution of the tumor volume depending on the type of protocol used. We can notice that the MTD protocol is clearly more ecient than the metronomic one at the beginning of the treatment, but due to resistance mechanisms, the cytotoxic eect of the MTD chemotherapy decreases after few cycles of treatment. Thus the metronomic protocol becomes more ecient than the MTD one after approximately 8 months. The tumor volume decreases in the metronomic protocol is mainly due to anti-angiogenic eect and thus is less sensible to acquired resistances. However, the decrease of the tumor volume in the metronomic protocol is very slow. We also note that the metronomic treatment fails at doses too low. It is interesting to observe that at the dose 65 mg/m 2 /day the tumor volume still grows though very slowly. This is a consequence of the probable existence of a biological threshold below which the drug loose its eciency. In the model, this fact is expressed through the presence of thresholds c min,ct and c min,aa .
Remark that the rules (5)-(6) are again satised for this chemotherapeutic agent.
Note that the pharmacodynamics as well as the pharmacokinetics of the drugs have not been taken into account in this work. The concentration C(t) of the drug is simply linked to the administered dose as shown in 
Conclusion and discussion
Nowadays, the paradigm of metronomic chemotherapies is a challenge in oncology, it would have good eciency while limiting toxicities. However, to improve the eciency of a metronomic chemotherapy, it is essential to be able to answer some clinical questions: What is a small dose? What is the most appropriate Furthermore, we exhibit here a good set of parameter values suitable for a glioblastoma non treated or treated by Temozolomide. In practice, there exists a huge variability of these parameters due to both the type of cancer or the diversity of metabolism in the patients. Thus a clinical transfer of such a huge system requires to reduce the set of parameters. A careful parametric study of the system as well as new biological quantitative rules will help us to identify a small set of parameters crucial for such dynamics.
Note that we present here results for tumors that are radially distributed, but of course the model could handle any kind of tumor shape, just by changing initial condition. In the same way, it could be interesting to take into account the heterogeneity of the tumor, by considering anisotropic diusion of the dierent quantities.
